

**Safety and Efficacy of long-term treatment with teneligliptin: Analysis of a post-marketing surveillance (PMS) of more than 10,000 Asian patients with type 2 diabetes mellitus (T2DM).**

Kadowaki T, *et al. Expert Opin Pharmacother.* 2018 Feb; 19(2): 83-91.

- **A 3-year PMS data analysis involving 10,532 subjects with T2DM (6,338 males/4,194 females) demonstrated the overall safety and efficacy of teneligliptin.** ADRs were reported in only 3.4% of the patients and serious ADRs in only 0.8%. The most common ADRs were hypoglycemia (0.32%) and constipation (0.27%).
- No change in mean body weight occurred, and a reduction in mean HbA1c was observed till 2 years.
- A subgroup analysis was also performed across three age groups (<65 years; 65 to <75 years; ≥75 years). The safety and efficacy profiles did not differ markedly among the three age groups.

*These interim results demonstrate that teneligliptin was well tolerated and improved hyperglycemia in patients with T2DM in clinical practice.*